Amgen stock slips as anemia drug concerns rise

An informal SEC inquiry into the way Amgen handled a Danish study of its anemia drug Aranesp has aroused investors' anxiety, spurring a three percent loss in the value of Amgen shares. Further adding to concerns about Amgen, an expert FDA panel is scheduled to review the safety of anemia drugs on May 10.

- take a look at the CNN report on the Amgen worries

ALSO: A possible change in Medicare's reimbursement formula for Epogen could reduce the amount of money that Amgen is making from the anemia therapy. Report

PLUS: Tony Blair opened Amgen's new European Development Centre in Uxbridge, London. Release

Related Articles:
FDA wants more data on new Aranesp doses. Report
New study points to danger of anemia drug. Report
Major challenges loom for Amgen. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.